PT3478712T - Anticorpos anti-péptido beta amiloide n3pglu e suas utilizações - Google Patents
Anticorpos anti-péptido beta amiloide n3pglu e suas utilizaçõesInfo
- Publication number
- PT3478712T PT3478712T PT177368412T PT17736841T PT3478712T PT 3478712 T PT3478712 T PT 3478712T PT 177368412 T PT177368412 T PT 177368412T PT 17736841 T PT17736841 T PT 17736841T PT 3478712 T PT3478712 T PT 3478712T
- Authority
- PT
- Portugal
- Prior art keywords
- amyloid beta
- beta peptide
- peptide antibodies
- n3pglu amyloid
- n3pglu
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357579P | 2016-07-01 | 2016-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3478712T true PT3478712T (pt) | 2023-08-21 |
Family
ID=59295341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT177368412T PT3478712T (pt) | 2016-07-01 | 2017-06-23 | Anticorpos anti-péptido beta amiloide n3pglu e suas utilizações |
Country Status (28)
Country | Link |
---|---|
US (2) | US11312763B2 (pt) |
EP (2) | EP4272828A3 (pt) |
JP (4) | JP7165588B2 (pt) |
KR (3) | KR20210024213A (pt) |
CN (3) | CN114887054A (pt) |
AU (1) | AU2017291414B2 (pt) |
BR (1) | BR112018073843A2 (pt) |
CA (1) | CA3029550C (pt) |
DK (1) | DK3478712T3 (pt) |
EA (1) | EA201892690A1 (pt) |
ES (1) | ES2958508T3 (pt) |
FI (1) | FI3478712T3 (pt) |
HR (1) | HRP20230861T1 (pt) |
HU (1) | HUE062980T2 (pt) |
IL (1) | IL263788B1 (pt) |
LT (1) | LT3478712T (pt) |
MA (1) | MA45543B1 (pt) |
MD (1) | MD3478712T2 (pt) |
MX (2) | MX2018016066A (pt) |
PL (1) | PL3478712T3 (pt) |
PT (1) | PT3478712T (pt) |
RS (1) | RS64386B1 (pt) |
SG (1) | SG11201810371XA (pt) |
SI (1) | SI3478712T1 (pt) |
TW (2) | TWI735600B (pt) |
UA (1) | UA127101C2 (pt) |
WO (1) | WO2018005282A1 (pt) |
ZA (1) | ZA201807633B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
EP3521308B1 (en) * | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
WO2019169448A1 (en) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Multi-specific antibodies |
JP2021532126A (ja) * | 2018-07-24 | 2021-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病の治療及び予防方法 |
CN111184725B (zh) * | 2020-02-27 | 2020-12-01 | 慈溪市人民医院医疗健康集团(慈溪市人民医院) | 一种防治脑梗塞的药物制剂及其制备方法 |
EP4274611A1 (en) * | 2021-01-11 | 2023-11-15 | Eli Lilly and Company | Anti-n3pglu amyloid beta antibodies and uses thereof |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
WO2023076970A1 (en) * | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
TW202336034A (zh) * | 2021-10-29 | 2023-09-16 | 美商美國禮來大藥廠 | 靶向介白素-34之化合物及方法 |
WO2023146818A2 (en) * | 2022-01-26 | 2023-08-03 | T3D Therapeutics, Inc. | Methods of treating amyloid related brain disorders using novel compounds and antibodies |
WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1397539A (en) * | 1920-01-14 | 1921-11-22 | Odell Risdon Moore | Egg-carton |
KR100767146B1 (ko) | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Aβ 펩티드를 격리시키는 인간화 항체 |
US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
EP1523499A2 (en) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
KR101068289B1 (ko) | 2004-07-30 | 2011-09-28 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법 |
UY30003A1 (es) | 2005-12-12 | 2007-08-31 | Hoffmann La Roche | Anticuerpos glicosilados en la region variable |
NZ567888A (en) | 2006-03-23 | 2010-08-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
ES2615454T3 (es) | 2007-01-18 | 2017-06-07 | Eli Lilly And Company | Fab pegilado contra el amiloide beta |
JP5889529B2 (ja) * | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
EP2310032A2 (en) | 2008-06-12 | 2011-04-20 | Affiris AG | Compounds for treating symptoms associated with parkinson's disease |
US20110182809A1 (en) | 2008-07-09 | 2011-07-28 | University Of Zurich | Method of Promoting Neurogenesis |
EA028427B1 (ru) | 2008-07-21 | 2017-11-30 | Пробиодруг Аг | АНТИТЕЛО, СВЯЗЫВАЮЩЕЕСЯ С Aβ-ПЕПТИДАМИ ИЛИ ИХ ВАРИАНТАМИ, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО, И ЕГО ПРИМЕНЕНИЕ |
CN101397539B (zh) * | 2008-10-14 | 2011-10-05 | 中国人民解放军第三军医大学 | 组织工程组织仿生培养的模拟人体生理应力的施力装置 |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011151076A2 (en) * | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
PT3339323T (pt) * | 2010-08-12 | 2020-01-14 | Lilly Co Eli | Anticorpos anti-péptido beta-amilóide n3pglu e seus usos |
WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
JP2016501247A (ja) | 2012-12-07 | 2016-01-18 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | 抗Aβ抗体を使用して脳アミロイド斑を減少させる方法 |
TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
SG10201901076WA (en) | 2014-02-08 | 2019-03-28 | Genentech Inc | Methods of treating alzheimer's disease |
WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
WO2015191825A1 (en) * | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
JP6201928B2 (ja) * | 2014-08-04 | 2017-09-27 | トヨタ自動車株式会社 | 車両制御装置 |
TWI570127B (zh) | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
WO2016053767A1 (en) | 2014-09-30 | 2016-04-07 | Merck Sharp & Dohme Corp. | Novel crystalline forms of a bace inhibitor, compositions, and their use |
MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
-
2017
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 IL IL263788A patent/IL263788B1/en unknown
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active IP Right Cessation
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active IP Right Grant
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 DK DK17736841.2T patent/DK3478712T3/da active
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Application Discontinuation
- 2017-06-23 CA CA3029550A patent/CA3029550C/en active Active
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 BR BR112018073843-3A patent/BR112018073843A2/pt unknown
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/en unknown
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/en active Pending
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/en active Active
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
-
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
-
2020
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/ja active Pending
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
-
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
-
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202007868B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
ZA201901207B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
IL263788A (en) | Anti-peptide n3pglu amyloid beta antibodies and their uses | |
ZA201801943B (en) | Anti¿lag3 antibodies and uses thereof | |
IL262095A (en) | Anti-pacap antibodies and their use | |
IL290783A (en) | Anti-tau antibodies and their uses | |
ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
HK1259324A1 (zh) | 澱粉樣蛋白β表位及其抗體 | |
HK1259325A1 (zh) | 澱粉樣蛋白β中的N-末端表位及其構象選擇性抗體 | |
EP3374380A4 (en) | C-TERMINAL EPITOPES IN BETA-AMYLOID AND RELATED CONFORMATIONAL ANTIBODIES | |
IL262244B1 (en) | Antibodies against beta interferon and their use | |
IL266049A (en) | Antibodies against o1 and their uses | |
EP3374382A4 (en) | BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES | |
IL266082A (en) | Anti-chikv antibodies and their use | |
IL264417A (en) | Anti-o2 antibodies and their uses | |
GB201519105D0 (en) | Antibody polypeptides and uses thereof | |
GB201517550D0 (en) | Antibody polypeptides and uses thereof |